Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

Pfizer is suing Johnson & Johnson, alleging that it induced US health insurers to help it block biosimilar competition to its blockbuster Remicade. Pfizer's Inflectra was the first monoclonal ...

The licensed dose of infliximab in AS (5 mg/kg at 6-week intervals, following loading infusions at 0, 2, and 6 weeks) is higher than for rheumatoid arthritis (RA) (3 mg/kg at 8-week intervals).

In our study 7/19 (37%) in the infliximab group received more than one infusion. The outcomes of these patients are as follows: two patients required colectomy after 106 and 291 days while the ...

Patients with Crohn's disease who lose some or all of their initial therapeutic response to infliximab can benefit from dose intensification. Regueiro et al. retrospectively analyzed 293 patients ...